Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
Chrome congestive heart failure
Activation and destruction of platelets in patients with rheumatic heart disease







*Departments of Central Clinical Laboratory 131 Sannomaru, Naka-ku, Nagoya 460
Cardiology, Meijo Hospital 131 Sannomaru, Naka-ku, Nagoya 460
Department of Internal Medicine, Branch Hospital, Nagoya University School of Medicine 1120 Daiko-Minami, Higashi-ku, Nagoya 461, Japan
Received 10 November 1992; revised 25 October 1993; .
Correspondence: Shinji Kunishisna, Department of Central Clinical Laboratory, Meijo Hospital, 1-3-1 Sannomaru, Naka-ku, Nagoya 460, Japan
Abstract
We evaluated the activation and destruction of platelets in 24 patients with rheumatic heart disease (RHD) involving the mitral valve. Ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and collagen was significantly increased in RHD patients as compared with normal controls. Plasma levels of ß-thromboglobulin (ß-TG) and platelet factor 4 were also elevated Plasma concentrations of glycocalicin, a proteolytic fragment of platelet membrane glycoprotein Ib. were increased, while platelet counts were decreased in RHD patients as compared with normal controls. RHD patients with, versus those without, atrial fibrillation demonstrated significant differences in ß-TG levels and platelet counts. However, we observed no difference in glycocalicin levels between the two groups. The present study demonstrated that increased platelet activation, as well as platelet destruction, occur in patients with RHD.
Key Words: Atrial fibrillation glycocalicin glycoprotein Ib platelet aggregation platelet factor 4 ß-thromboglobulin
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Topaloglu, A. Boyaci, S. Ayaz, S. Yilmaz, O. Yanik, O. Ozdemir, M. Soylu, A. D. Demir, D. Aras, H. L. Kisacik, et al. Coagulation, Fibrinolytic System Activation and Endothelial Dysfunction in Patients With Mitral Stenosis and Sinus Rhythm Angiology, February 1, 2007; 58(1): 85 - 91. [Abstract] [PDF] |
||||
![]() |
M.-C. Chen, H.-W. Chang, C.-J. Wu, C.-H. Yang, W. C. Hung, K.-H. Yeh, and M. Fu Percutaneous Transluminal Mitral Valvuloplasty Reduces Circulating Soluble CD40 Ligand in Rheumatic Mitral Stenosis Chest, July 1, 2005; 128(1): 36 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Chen, H.-W. Chang, S.-S. Juang, H.-K. Yip, and C.-J. Wu Increased Plasma Levels of Soluble P-Selectin in Rheumatic Mitral Stenosis Chest, July 1, 2004; 126(1): 54 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Chen, C.-J. Wu, H.-W. Chang, H.-K. Yip, Y.-H. Chen, C.-I Cheng, and H.-T. Chai Mechanism of Reducing Platelet Activity by Percutaneous Transluminal Mitral Valvuloplasty in Patients With Rheumatic Mitral Stenosis Chest, May 1, 2004; 125(5): 1629 - 1634. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Chen, C.-J. Wu, H.-K. Yip, H.-W. Chang, C.-Y. Fang, T.-H. Yu, and M. Fu Left Atrial Platelet Activity With Rheumatic Mitral Stenosis: Correlation Study of Severity and Platelet P-Selectin Expression by Flow Cytometry Chest, November 1, 2003; 124(5): 1663 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kamath, A. D. Blann, B. S. P. Chin, F. Lanza, B. Aleil, J. P. Cazenave, and G. Y. H. Lip A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy Eur. Heart J., November 2, 2002; 23(22): 1788 - 1795. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kamath, A.D. Blann, and G.Y.H. Lip Platelets and atrial fibrillation Eur. Heart J., December 2, 2001; 22(24): 2233 - 2242. [PDF] |
||||


